⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
LLY News
Eli Lilly & Co.
Lilly to build $6 billion facility to manufacture active pharmaceutical ingredients in Alabama
prnewswire.com
LLY
Amid Escalating Market Investment, Physicians Forecast Rapid Uptake of Oral Semaglutide Upon Approval in Obesity, According to Spherix Global Insights
globenewswire.com
NVO
LLY
Global Medical Device Contract Manufacturing Market is Predicted to Cross the USD 190 Billion Mark by 2032, Owing to the Rising Demand for Advanced Healthcare Solutions | DelveInsight
globenewswire.com
TMO
PFE
AMGN
BMY
MRK
DHR
ABBV
GOOG
MSFT
JNJ
MDT
BSX
SYK
EW
ISRG
EMR
BIOX
EXAS
QRVO
TER
ADI
TXN
ON
INTC
NVDA
AMD
HPQ
DELL
IBM
GE
FISV
ADP
PAYX
NOW
CRM
ORCL
SAP
ADSK
CDNS
SNPS
AMAT
INFY
HPE
LOGI
ATHM
BIIB
GILD
REGN
VRTX
AMRN
AZN
LLY
NVS
CRSP
EDIT
NTLA
ALNY
INCY
XRAY
COO
MASI
IRTC
MRNA
EMB
ADMA
ICUI
HOLX
LH
DGX
RDNT
EVTC
AFYA
CHKP
DDOG
SMCI
ALGN
THRY
PTC
MCHP
NXPI
QCOM
SWKS
MU
WDC
STX
Lilly and Adverum announce expiration and completion of Adverum tender offer and acquisition
prnewswire.com
LLY
ADVM
AMERICAN WRITERS MUSEUM’S NEW SPECIAL EXHIBIT AMERICAN PROPHETS: WRITERS, RELIGION, AND CULTURE NOW OPEN THROUGH NOVEMBER 2026
globenewswire.com
LLY
Ability Biotherapeutics nomme Angèle Maki, Ph. D., au poste de cheffe de la direction commerciale
businesswire.com
BMY
GENK
MRK
LLY
Pirtobrutinib Outperforms Bendamustine Plus Rituximab for Previously Untreated CLL/SLL
prnewswire.com
LLY
Lilly's Jaypirca (pirtobrutinib) significantly improved progression-free survival, reducing the risk of progression or death by 80%, versus chemoimmunotherapy in patients with treatment-naïve CLL/SLL
prnewswire.com
LLY
Lilly declares first-quarter 2026 dividend
prnewswire.com
LLY
Eczema Clinical Trial Pipeline Accelerates as 100+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight
globenewswire.com
AMGN
PFE
LLY
AZN
BMY
NVS
SNY
GSK
UCB
ARQT
REGN
INCY
ABBV
BIIB
MRK
JNJ
VNDA
RAPT
CHAI
ONON
ION
ASMB
CRVS
APG
KSCP
KYMR
XBI
IBB
ADSK
CDNS
SNPS